Latest Research And Development News

Elixir Energy has successfully completed a key pressure test on its Lorelle-3H well in Queensland’s Taroom Trough, confirming reservoir conditions and increasing planned stimulation stages from 11 to 12. Stimulation operations are set to start imminently, aiming to prove commercial gas and condensate flow.

Temas Resources is on track to fully commission its Ontario metallurgical lab by July 2026, initiating large-scale testing of La Blache project material to refine its proprietary RCL technology and support commercialization.

EBR Systems has kicked off a fully underwritten 1-for-2 entitlement offer priced at $0.38 per CDI, aiming to raise $85.6 million to accelerate commercialisation and manufacturing of its wireless cardiac pacing technology.

CleanSpace Holdings has achieved a major regulatory milestone with European EN 12941 certification for its new AGILE loose-fitting PAPR, positioning the company for growth in its largest market and preparing for imminent Australian approval.

Island Pharmaceuticals is accelerating development of its broad-spectrum antiviral Galidesivir, progressing clinical, regulatory, and manufacturing milestones under the FDA Animal Rule pathway with expanded USAMRIID collaboration and biodefence positioning.

Island Pharmaceuticals has expanded its partnership with USAMRIID to conduct a pivotal Galidesivir dose optimisation study against Marburg virus, targeting topline results in the second half of 2026.

Boresight Ltd (ASX: BST) is seeking to raise $8 million through a public offer to expand its cost-effective military drone manufacturing, targeting growth in the US and European markets.

Elixir Energy has kicked off the stimulation and testing phase at its Lorelle-3H appraisal well, aiming to validate commercial gas and condensate flow rates from Queensland’s Taroom Trough basin-centred gas play.

Aurora Labs has landed a $1 million Australian Government grant, matched dollar-for-dollar, to boost production of its micro gas turbine propulsion systems for defence applications using commercial 3D printing technology.

Amplia Therapeutics reported encouraging mature data from its ACCENT pancreatic cancer trial showing improved survival and response rates with narmafotinib. The company raised $27.5 million to fund development and manufacturing scale-up, while discontinuing a parallel trial due to chemotherapy toxicity.

TradeWindow reported a 20% rise in FY26 revenue to NZ$9.6 million with annual recurring revenue surpassing NZ$10 million. The company narrowed its EBITDA loss and is targeting breakeven in FY27 while advancing its AI-driven FreightAI platform.

Pure Resources (ASX: PR1) has closed a $3 million placement, issuing 12 million shares after shareholder approval, while also issuing options and advisory shares to support exploration and cutting-edge carbon nanotube fibre research.